Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Interaction of a Cyclic, Bivalent Smac Mimetic with the X-Linked Inhibitor of Apoptosis Protein

Journal Article · · Biochemistry-US
DOI:https://doi.org/10.1021/bi800785y· OSTI ID:1006992
We have designed and synthesized a cyclic, bivalent Smac mimetic (compound 3) and characterized its interaction with the X-linked inhibitor of apoptosis protein (XIAP). Compound 3 binds to XIAP containing both BIR2 and BIR3 domains with a biphasic dose-response curve representing two binding sites with IC{sub 50} values of 0.5 and 406 nM, respectively. Compound 3 binds to XIAPs containing the BIR3-only and BIR2-only domain with K{sub i} values of 4 nM and 4.4 {mu}M, respectively. Gel filtration experiments using wild-type and mutated XIAPs showed that 3 forms a 1:2 stoichiometric complex with XIAP containing the BIR3-only domain. However, it forms a 1:1 stoichiometric complex with XIAP containing both BIR2 and BIR3 domains, and both BIR domains are involved in the binding. Compound 3 efficiently antagonizes inhibition of XIAP in a cell-free functional assay and is >200 times more potent than its corresponding monovalent compound 2. Determination of the crystal structure of 3 in complex with the XIAP BIR3 domain confirms that 3 induces homodimerization of the XIAP BIR3 domain and provides a structural basis for the cooperative binding of one molecule of compound 3 to two XIAP BIR3 molecules. On the basis of this crystal structure, a binding model of XIAP containing both BIR2 and BIR3 domains and 3 was constructed, which sheds light on the ability of 3 to relieve the inhibition of XIAP with not only caspase-9 but also caspase-3/-7. Compound 3 is cell-permeable, effectively activates caspases in whole cells, and potently inhibits cancer cell growth. Compound 3 is a useful biochemical and pharmacological tool for further elucidating the role of XIAP in regulation of apoptosis and represents a promising lead compound for the design of potent, cell-permeable Smac mimetics for cancer treatment.
Research Organization:
Advanced Photon Source (APS), Argonne National Laboratory (ANL), Argonne, IL (US)
Sponsoring Organization:
USDOE
OSTI ID:
1006992
Journal Information:
Biochemistry-US, Journal Name: Biochemistry-US Journal Issue: (37) ; 2008 Vol. 47; ISSN 0006-2960; ISSN BICHAW
Country of Publication:
United States
Language:
ENGLISH

Similar Records

The structure of the BIR3 domain of cIAP1 in complex with the N-terminal peptides of SMAC and caspase-9
Journal Article · Wed Jun 24 00:00:00 EDT 2009 · Acta Crystallogr. D · OSTI ID:1018556

Structure-Activity Based Study of the Smac-Binding Pocket Within the DIR3 Domain of XIAP
Journal Article · Sun Dec 31 23:00:00 EST 2006 · BioOrganic and Medicinal Chemistry Letters · OSTI ID:930397

Pharmacology of smac mimetics; chemotype differentiation based on physical association with caspase regulators and cellular transport
Journal Article · Sun Nov 01 00:00:00 EDT 2015 · Experimental Cell Research · OSTI ID:22746376